Literature DB >> 19261802

Oseltamivir-resistant influenza a viruses circulating in Japan.

Daisuke Tamura1, Keiko Mitamura, Masahiko Yamazaki, Motoko Fujino, Mari Nirasawa, Kazuhiro Kimura, Maki Kiso, Hideaki Shimizu, Chiharu Kawakami, Satoshi Hiroi, Kazuro Takahashi, Mami Hata, Hiroko Minagawa, Yoshiaki Kimura, Satoko Kaneda, Shigeo Sugita, Taisuke Horimoto, Norio Sugaya, Yoshihiro Kawaoka.   

Abstract

Surveillance studies of the influenza viruses circulating in Europe and other countries in 2007 and 2008 have revealed rates of resistance to oseltamivir of up to 67% among H1N1 viruses. In the present study, we examined 202 clinical samples obtained from patients infected with H1N1 virus in Japan in 2007 and 2008 for oseltamivir resistance and found that three were oseltamivir resistant (1.5%). The 50% inhibitory concentrations (IC(50)s), as measured by a sialidase inhibition assay with these drug-resistant viruses, were >100-fold higher than those of the nonresistant viruses (median IC(50), 12.6 nmol/liter). The His274Tyr (strain N2 numbering) mutation of the neuraminidase protein, which is known to confer oseltamivir resistance, was detected in these three isolates. Phylogenetic analysis showed that one virus belonged to a lineage that is composed of drug-resistant viruses isolated in Europe and North America and that the other two viruses independently emerged in Japan. Continued surveillance studies are necessary to observe whether these viruses will persist.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261802      PMCID: PMC2681884          DOI: 10.1128/JCM.02396-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006-2007 influenza season in Japan.

Authors:  Reiko Saito; Yasushi Suzuki; Danjuan Li; Hassan Zaraket; Isamu Sato; Hironori Masaki; Takashi Kawashima; Shigeyoshi Hibi; Yasuko Sano; Yugo Shobugawa; Taeko Oguma; Hiroshi Suzuki
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

2.  High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.

Authors:  Reiko Saito; Danjuan Li; Yasushi Suzuki; Isamu Sato; Hironori Masaki; Hidekazu Nishimura; Takashi Kawashima; Yutaka Shirahige; Chieko Shimomura; Norichika Asoh; Satoshi Degawa; Hidefumi Ishikawa; Maki Sato; Yugo Shobugawa; Hiroshi Suzuki
Journal:  J Med Virol       Date:  2007-10       Impact factor: 2.327

3.  Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

Authors:  Larisa V Gubareva; Robert G Webster; Frederick G Hayden
Journal:  Antiviral Res       Date:  2002-01       Impact factor: 5.970

4.  Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule.

Authors:  J W Yewdell; R G Webster; W U Gerhard
Journal:  Nature       Date:  1979-05-17       Impact factor: 49.962

5.  Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

Authors:  Shuji Hatakeyama; Norio Sugaya; Mutsumi Ito; Masahiko Yamazaki; Masataka Ichikawa; Kazuhiro Kimura; Maki Kiso; Hideaki Shimizu; Chiharu Kawakami; Kazuhiko Koike; Keiko Mitamura; Yoshihiro Kawaoka
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

6.  Resistant influenza A viruses in children treated with oseltamivir: descriptive study.

Authors:  Maki Kiso; Keiko Mitamura; Yuko Sakai-Tagawa; Kyoko Shiraishi; Chiharu Kawakami; Kazuhiro Kimura; Frederick G Hayden; Norio Sugaya; Yoshihiro Kawaoka
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

7.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

Authors:  M Louise Herlocher; Rachel Truscon; Stephanie Elias; Hui-Ling Yen; Noel A Roberts; Suzanne E Ohmit; Arnold S Monto
Journal:  J Infect Dis       Date:  2004-09-28       Impact factor: 5.226

8.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Estimating the impact of school closure on influenza transmission from Sentinel data.

Authors:  Simon Cauchemez; Alain-Jacques Valleron; Pierre-Yves Boëlle; Antoine Flahault; Neil M Ferguson
Journal:  Nature       Date:  2008-04-10       Impact factor: 49.962

10.  High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza.

Authors:  Kyoko Shiraishi; Keiko Mitamura; Yuko Sakai-Tagawa; Hideo Goto; Norio Sugaya; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

View more
  18 in total

1.  Detection and pathogenesis of a novel swine H3N2 influenza virus containing three genes from the 2009 pandemic H1N1 influenza viruses in Korea in 2015.

Authors:  Tran Bac Le; In Hong Lee; Byung Jun Kim; Hyun Soo Kim; Sang Heui Seo
Journal:  Virol Sin       Date:  2016-12       Impact factor: 4.327

Review 2.  Passive immune neutralization strategies for prevention and control of influenza A infections.

Authors:  Jianqiang Ye; Hongxia Shao; Daniel R Perez
Journal:  Immunotherapy       Date:  2012-02       Impact factor: 4.196

3.  Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.

Authors:  Daisuke Tamura; Norio Sugaya; Makoto Ozawa; Ryo Takano; Masataka Ichikawa; Masahiko Yamazaki; Chiharu Kawakami; Hideaki Shimizu; Ritei Uehara; Maki Kiso; Eiryo Kawakami; Keiko Mitamura; Yoshihiro Kawaoka
Journal:  Clin Infect Dis       Date:  2011-01-19       Impact factor: 9.079

4.  Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.

Authors:  C Renaud; S A Pergam; C Polyak; R Jain; J Kuypers; J A Englund; L Corey; M J Boeckh
Journal:  Transpl Infect Dis       Date:  2010-11-10       Impact factor: 2.228

5.  Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses.

Authors:  Hassan Zaraket; Reiko Saito; Yasushi Suzuki; Tatiana Baranovich; Clyde Dapat; Isolde Caperig-Dapat; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

6.  A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.

Authors:  Yoko Matsuzaki; Katsumi Mizuta; Yoko Aoki; Asuka Suto; Chieko Abiko; Kanako Sanjoh; Kanetsu Sugawara; Emi Takashita; Tsutomu Itagaki; Yuriko Katsushima; Makoto Ujike; Masatsugu Obuchi; Takato Odagiri; Masato Tashiro
Journal:  Virol J       Date:  2010-03-05       Impact factor: 4.099

7.  Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.

Authors:  Maki Kiso; Shuku Kubo; Makoto Ozawa; Quynh Mai Le; Chairul A Nidom; Makoto Yamashita; Yoshihiro Kawaoka
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

8.  Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Authors:  Aeron C Hurt; Jessica K Holien; Michael Parker; Anne Kelso; Ian G Barr
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

9.  Modelling and analysing the coexistence of dual dilemmas in the proactive vaccination game and retroactive treatment game in epidemic viral dynamics.

Authors:  K M Ariful Kabir; Jun Tanimoto
Journal:  Proc Math Phys Eng Sci       Date:  2019-12-04       Impact factor: 2.704

10.  A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.

Authors:  Makoto Ozawa; Masayuki Shimojima; Hideo Goto; Shinji Watanabe; Yasuko Hatta; Maki Kiso; Yousuke Furuta; Taisuke Horimoto; Noel R Peters; F Michael Hoffmann; Yoshihiro Kawaoka
Journal:  Sci Rep       Date:  2013-01-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.